For research use only. Not for therapeutic Use.
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer[1].
BAY-8400 (150 mg/kg; p.o.) increases the antitumor efficacy. BAY-8400 shows useful aqueous
solubility and oral bioavailability across species[1].
| Catalog Number | I045390 |
| CAS Number | 2763602-59-9 |
| Synonyms | 8-[5-(difluoromethyl)pyridin-3-yl]-1-(2,3,6,7-tetrahydrooxepin-4-yl)-[1,2,4]triazolo[4,3-a]quinoxaline |
| Molecular Formula | C21H17F2N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C21H17F2N5O/c22-20(23)16-8-15(10-24-11-16)14-3-4-17-18(9-14)28-19(12-25-17)26-27-21(28)13-2-1-6-29-7-5-13/h2-4,8-12,20H,1,5-7H2 |
| InChIKey | ATKHYZXUMVNCIO-UHFFFAOYSA-N |
| SMILES | C1COCCC(=C1)C2=NN=C3N2C4=C(C=CC(=C4)C5=CC(=CN=C5)C(F)F)N=C3 |
| Reference | [1]. Berger M, et al. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies [published online ahead of print, 2021 Aug 24]. J Med Chem. 2021;10.1021/acs.jmedchem.1c00762. |
